{"id":"icosapent-mnd-2119","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding or bruising"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Fishy aftertaste"}]},"_chembl":{"chemblId":"CHEMBL2095209","moleculeType":"Small molecule","molecularWeight":"330.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Icosapent (EPA) works by increasing EPA levels in the bloodstream, which helps reduce triglyceride synthesis in the liver and promotes triglyceride clearance. It also has anti-inflammatory and antiplatelet properties that may contribute to cardiovascular benefits beyond simple triglyceride lowering.","oneSentence":"Icosapent is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:24.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertriglyceridemia in patients with elevated cardiovascular risk"}]},"trialDetails":[{"nctId":"NCT04221217","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Mochida Pharmaceutical Company, Ltd.","startDate":"2020-02-14","conditions":"Hypertriglyceridemia","enrollment":120},{"nctId":"NCT03693131","phase":"PHASE3","title":"Efficacy of MND-2119 in Participants With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Mochida Pharmaceutical Company, Ltd.","startDate":"2018-10-27","conditions":"Hypertriglyceridemia","enrollment":580}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Icosapent (MND-2119)","genericName":"Icosapent (MND-2119)","companyName":"Mochida Pharmaceutical Company, Ltd.","companyId":"mochida-pharmaceutical-company-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Icosapent is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism. Used for Hypertriglyceridemia in patients with elevated cardiovascular risk.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}